Detection of Amplification of Her2 Fluorescent in Situ Hybridization (FISH) in Breast Tissue Sections (Her2F test)
This study has been completed.
Sponsor:
Applied Spectral Imaging Ltd.
Information provided by:
Applied Spectral Imaging Ltd.
ClinicalTrials.gov Identifier:
NCT01066507
First received: February 9, 2010
Last updated: NA
Last verified: February 2010
History: No changes posted
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
![](https://webarchive.library.unt.edu/web/20121019014826im_/http://www.clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
The purpose of the study is the identification of amplification level in human breast tissue. The imaging system is intended for diagnostic use as an aid to the pathologist in the detection, counting and classification of Her2 FISH stained tissue samples.
Condition |
---|
Breast Cancer |
Study Type: | Observational |
Study Design: | Observational Model: Case Control Time Perspective: Retrospective |
Official Title: | Concordance Study for Amplification Detection of Her2 FISH in Breast Tissue Sections |
Resource links provided by NLM:
Further study details as provided by Applied Spectral Imaging Ltd.:
Biospecimen Retention: Samples Without DNA
Paraffin embedded tissue sections
Enrollment: | 126 |
Study Start Date: | July 2008 |
Study Completion Date: | January 2010 |
Primary Completion Date: | January 2010 (Final data collection date for primary outcome measure) |
Groups/Cohorts |
---|
Breast cancer
Slides containing breast cancer paraffin embedded tissue sections.
|
![](https://webarchive.library.unt.edu/web/20121019014826im_/http://www.clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
Ages Eligible for Study: | 21 Years and older |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Study Population
The breast samples were taken from female patients after cut biopsies. Paraffin embedded blocks were prepared and the secssion slides were stained with the PathVysion prove for Her2 FISH applification detection
Criteria
Inclusion Criteria:
- Well stained breast tissue slides with bright Her2 signals
Exclusion Criteria:
- Very old slides that were already bleached
![](https://webarchive.library.unt.edu/web/20121019014826im_/http://www.clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
Please refer to this study by its ClinicalTrials.gov identifier: NCT01066507
Locations
United States, New Jersey | |
PLUS Diagnostics | |
Lakewood, New Jersey, United States, 08701 | |
United States, Texas | |
Scott & White Hospital, Texas | |
Temple, Texas, United States, 76508 | |
Israel | |
Sheba Medical Center, Pathology Dep. | |
Tel Aviv, Israel |
Sponsors and Collaborators
Applied Spectral Imaging Ltd.
Investigators
Study Director: | Sheila Dobin, Ph.D. | Section Chief, Cytogenetics |
![](https://webarchive.library.unt.edu/web/20121019014826im_/http://www.clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
No publications provided
Responsible Party: | Tsafrir Kolatt, Applied Spectral Imaging Ltd. |
ClinicalTrials.gov Identifier: | NCT01066507 History of Changes |
Other Study ID Numbers: | ASI-Her2F |
Study First Received: | February 9, 2010 |
Last Updated: | February 9, 2010 |
Health Authority: | United States: Institutional Review Board |
Keywords provided by Applied Spectral Imaging Ltd.:
Her2 FISH Breast cancer Amplification |
Additional relevant MeSH terms:
Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases |
ClinicalTrials.gov processed this record on October 17, 2012